Scynexis Inc - Company Profile
Powered by 
All the sales intelligence you need on Scynexis Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Scynexis Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Scynexis Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Scynexis Inc (Scynexis) is a pharmaceutical company that discovers, develops and commercializes novel anti-infectives for multiple serious fungal infections. It develops fungerps, a novel class of triterpenoid antifungal agents, distinct glucan synthase inhibitors effective against various fungal pathogens. The company offers products such as BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections. Scynexis other pipeline includes SCY-247 for the treatment of Candida auris and other drug-resistant fungal infections. The company also carries out clinical trials for its pipeline product in patients with invasive pulmonary aspergillosis, intolerant fungal diseases and candidiasis among others. Scynexis is headquartered in Jersey City, New Jersey, the US.
Headquarters
United States of America
Address
13th Floor, 1 Evertrust Plaza, Jersey City, New Jersey, 07302
Website
www.scynexis.com/
Telephone
1 201 8845485
No of Employees
18
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SCYX (NASD)
Revenue (2024)
$20.6M
449.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
59.6%
(2024 vs 2023)
Market Cap*
$42.0M
Net Profit Margin (2024)
XYZ
92.7%
(2024 vs 2023)
* As of and is in US$
Scynexis Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | BREXAFEMME |
| BREXAFEMME (Ibrexafungerp Tablets): Invasive Candidiasis and Other Refractory Fungal Infections, Vulvovaginal Candidiasis | |
| SCY-247: Candida Auris and Other Drug-Resistant Fungal Infections | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In June, the company entered into an agreement with GSK for ibrexafungerp. |
| 2021 | Contracts/Agreements | In February, the company entered into a licensing agreement and strategic partnership with Hansoh Pharmaceutical Group Company Limited to research, develop and commercialize ibrexafungerp in the Greater China region. |
| 2016 | Others | In April, Scynexis, Inc. received Small and Medium Sized Enterprise (SME) status from European Medicines Agency (EMA) to support the development of medicines. |
Competitor Comparison
| Key Parameters | Scynexis Inc | Merck & Co Inc | Pfizer Inc | Gilead Sciences Inc | Trevena Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Jersey City | Rahway | New York City | Foster City | Atlanta |
| State/Province | New Jersey | New Jersey | New York | California | Georgia |
| No. of Employees | 18 | 75,000 | 75,000 | 17,000 | 23 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Guy Macdonald | Chairman | Executive Board | 2014 | 67 |
| David Angulo, M.D. | Chief Executive Officer; Director; President | Executive Board | 2014 | 61 |
| Ivor Macleod | Chief Financial Officer | Senior Management | 2022 | 65 |
| Scott Sukenick | Chief Legal Officer | Senior Management | 2023 | 48 |
| Daniella Gigante | Vice President - Human Resources and Information Technology | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer